{"id":"NCT04024228","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","officialTitle":"Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-28","primaryCompletion":"2020-01-09","completion":"2020-06-05","firstPosted":"2019-07-18","resultsPosted":"2021-01-19","lastUpdate":"2023-10-03"},"enrollment":1539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza Immunization","Healthy Volunteers"],"interventions":[{"type":"BIOLOGICAL","name":"Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)","otherNames":["Influvacâ„¢ Tetra"]},{"type":"BIOLOGICAL","name":"High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation","otherNames":[]}],"arms":[{"label":"Group 1: QIV-HD","type":"EXPERIMENTAL"},{"label":"Group 2: QIV-SD","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate that high-dose quadrivalent influenza vaccine (QIV-HD) induces an immune response that is superior to the responses induced by standard-dose quadrivalent influenza vaccine (QIV-SD) for all 4 virus strains 28 days post-vaccination in participants 60 to 64 years of age and in participants 65 years of age and older.\n\nSecondary Objective:\n\n* Immunogenicity: To further describe the immune response induced by QIV-HD and QIV-SD in all participants by age group, in pooled age groups, and by vaccine group (QIV-HD; QIV-SD).\n* Safety: To describe the safety profile of all participants by age group, in pooled age groups, and by vaccine group (QIV-HD; QIV-SD).","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Influenza Antibodies in Participants Aged 60-64 Years and Greater Than or Equal to (>=) 65 Years","timeFrame":"Day 28 post-vaccination","effectByArm":[{"arm":"Group 1: QIV-HD","deltaMin":471,"sd":null},{"arm":"Group 2: QIV-SD","deltaMin":248,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":17,"countries":["Belgium","France","Germany","Italy","Netherlands","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":772},"commonTop":["Injection Site Pain","Headache","Myalgia","Malaise","Injection Site Erythema"]}}